Abattis Bioceuticals EBIT

The latest EBIT for ATTBF is $-3.9M as of September 2019. That compares with $-17M in the prior-year period — up 77.5% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Abattis Bioceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ATTBF's EBIT moved from $-17M to $-3.9M — a 77.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Abattis Bioceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ATTBF currently prints $-3.9M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Abattis Bioceuticals's growth, margins, and balance sheet.

A EBIT figure of $-3.9M for ATTBF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting ATTBF's EBIT ($-3.9M), review year-over-year change from $-17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.